GlassScriptPhysician profile
Lisa H Ma
NPI 1639125487
$4,663.30
in general payments reported to CMS, 2019-2025
34 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $582 · 2021: $647 · 2022: $423 · 2023: $690 · 2024: $823 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.89 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $352.52 | 2019-2021 | |
| Lilly USA, LLC | $326.80 | 2019-2025 | Zepbound, Mounjaro, Lyumjev |
| Horizon Therapeutics Plc | $300.10 | 2022-2023 | Krystexxa |
| Allergan, INC. | $267.76 | 2019-2020 | |
| Novo Nordisk INC | $249.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $247.82 | 2023-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $209.44 | 2020-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Corcept Therapeutics | $197.45 | 2019-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.60 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $152.56 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $120.15 | 2022 | |
| Aimmune Therapeutics, INC. | $104.89 | 2024-2025 | Zenpep, Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.64 | 2021-2024 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $88.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $77.84 | 2021-2025 | Minimed 780g |
| Pfizer INC. | $71.22 | 2021-2023 | |
| Amgen INC. | $68.04 | 2024-2025 | Krystexxa |
| Phadia US INC. | $62.56 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.17 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $49.13 | 2020-2023 | Rexulti |
| Glaxosmithkline, LLC. | $49.03 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $44.96 | 2020 | |
| Abbott Laboratories | $42.97 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $38.98 | 2021-2025 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $32.25 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.57 | 2024 | Caplyta |
| Neurocrine Biosciences, INC. | $28.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $26.41 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $19.31 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.22 | 2019 | |
| Valeritas, INC. | $12.96 | 2019 | |
| Therapeuticsmd, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.